OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Reviews Drug Discovery is 80. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
AI serves up target and inhibitor for lung fibrosis	2298
Vaccine exposes tumours to immune cell attack	1342
Pfizer buys Biohaven’s migraine drugs for $11.6 billion	880
The importance of persistence in cancer drug development	756
A specific biomarker for insoluble tau	737
Targeting tumour-associated bacteria	592
A new path to targeted protein degradation?	566
Neutralizing Zika virus	560
The improving benefit–risk balance of phase I cancer trials	548
FDA approves a c-MET-targeted ADC for lung cancer	515
Tumour cells get a dendritic cell makeover	494
Glucose-sensitive insulin protects against hypoglycaemia	468
Promoting tissue repair after heart attack	454
mRNA-encoded monoclonal antibody fights CHIKV	424
Hypoimmune iPSCs escape immune detection	405
Lipid nanoparticle ferries therapeutic mRNA to the placenta	362
Targeting drug-resistant glioblastoma	353
FDA new drug approvals in Q1 2023	335
Apolipoprotein L2 inhibitor mitigates fibrosis	334
Chemical engineering of CRISPR–Cas systems for therapeutic application	315
Degrading cell-free DNA to prevent recurrent stroke	314
FDA approves second TTR stabilizer for cardiac amyloidosis	294
Top companies and drugs by sales in 2021	290
First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancer	290
New antibiotic for urinary tract infections nabs FDA approval	288

BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approval	279
Anti-tau antibody stumbles in phase II Alzheimer trial	273
Small-molecule discovery through DNA-encoded libraries	262
Evolution of innovative drug R&D in China	255
2022 FDA approvals	243
mRNA vaccines for infectious diseases — advances, challenges and opportunities	242
Targeting the Hippo pathway in cancer	231
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets	229
Increasing the potency of T cell therapies	229
Small molecule improves muscle function in myasthenia gravis	228
Blocking breast cancer metastasis	216
Pushing both sides of the drug pricing aisle	200
FDA approves anti-CD3 antibody to delay type 1 diabetes onset	200
Host-directed antiviral blocks SARS-CoV-2 entry	195
TCR-engineered T cells get personal	194
FDA new drug approvals in Q2 2023	183
Inhibiting ASGR1 boosts cholesterol removal	180
Rewired proteostasis in KRAS inhibitor resistance	173
Author Correction: Identification of neoantigens for individualized therapeutic cancer vaccines	173
R&D re-balancing act	169
A call to action for translational sciences in COVID-19 and future pandemics	159
FDA approves first DLL3 × CD3 bispecific T-cell engager for lung cancer	155
Mimicking the health benefits of exercise	155
Screening ultra-large virtual libraries	155
FDA approves second BCMA-targeted CAR-T cell therapy	153
A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics	149
Reflections on 10 years of the FDA’s breakthrough therapy designation	144
Pan-coronavirus vaccine pipeline takes form	142
Phenotypic drug discovery: recent successes, lessons learned and new directions	141
The antibody–drug conjugate landscape	140
Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape	138
Combating antimicrobial resistance in malaria, HIV and tuberculosis	130
Base editors hit the clinic	125
Amylin takes another shot at the obesity prize	120
The significance of blockbusters in the pharmaceutical industry	114
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders	112
‘Bespoke Gene Therapy Consortium’ sets out to enable gene therapies for ultra-rare diseases	108
The emerging role of mass spectrometry-based proteomics in drug discovery	105
The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap	105
Antibody–drug conjugates come of age in oncology	104
Multi-TACs target solid tumours	104
Immunology on the brain	103
Gut metabolite mediates nerve repair	99
Reducing IL-2 toxicity	98
Agonist antibody lowers blood pressure	95
FDA approves first-in-class TRPM8 ion channel agonist for dry eye disease	93
Oral IL-23-blocking peptide racks up phase III wins in inflammatory disease	91
Monkeypox mRNA vaccine protects mice and macaques	91
Neglected tropical diseases go global	89
FDA approves J&J’s FcRn blocker for generalized myasthenia gravis	87

Anti-IL-11 antibody shows anti-ageing properties	85
GSK buys Affinivax for up to $3.3 billion, bolstering its vaccine pipeline	85
Ribosome inhibitor combats bacterial drug resistance	84
The malignant melanoma market	83
LRRK2-targeted Parkinson disease drug advances into phase III	82
Targeting the ECM in melanoma	80
Frameworks for transformational breakthroughs in RNA-based medicines	80